Eli Lilly: positive results from two mirikizumab studies

(CercleFinance.com) - Eli Lilly announces the results of two Phase 3 studies showing that patients treated with mirikizumab maintained stable long-term remission in two types of inflammatory bowel disease (IBD): ulcerative colitis (UC) and Crohn's disease.


Study data will be presented at the annual meeting of the American College of Gastroenterology (ACG) in Philadelphia, 25-30 October 2024.

In one study, mirikizumab achieved long-term results for UC patients, with 81% maintaining clinical remission. In Crohn's disease, results from the Phase 2 program show that 96% of treated patients responded clinically, and 54% achieved endoscopic remission after three years of treatment.

This data shows that mirikizumab is a targeted therapy that can provide intestinal healing over time, the Icahn Institute of Medicine at Mount Sinai said.

The laboratory anticipates additional regulatory submissions for Crohn's disease worldwide.


Copyright (c) 2024 CercleFinance.com. All rights reserved.